Claim 50% Off TipRanks Premium and Invest with Confidence
- Unlock hedge-fund level data and powerful investing tools designed to help you make smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis so your portfolio is always positioned for maximum potential
China Resources Pharmaceutical Group Ltd. ( (HK:3320) ) has shared an update.
China Resources Pharmaceutical Group Ltd. announced a change in its executive leadership, with Mdm. Deng Rong resigning as an executive director and member of the executive committee, while continuing her role as CFO. Concurrently, Mr. Liu Changan has been appointed as an executive director and member of the executive committee, bringing his experience from previous roles within the company and other organizations. These changes are expected to maintain the company’s strategic direction and stability, ensuring continued focus on its growth and operational goals.
More about China Resources Pharmaceutical Group Ltd.
China Resources Pharmaceutical Group Ltd. operates in the pharmaceutical industry, focusing on the development, manufacturing, and distribution of pharmaceutical products. The company is known for its comprehensive range of healthcare products and services, catering to a broad market with a focus on innovation and quality.
Average Trading Volume: 14,994,136
Technical Sentiment Signal: Sell
Current Market Cap: HK$31.22B
Find detailed analytics on 3320 stock on TipRanks’ Stock Analysis page.